CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
We are pleased to inform you that the Canadian Cancer Trials Group (CCTG) is organizing our next Clinical Research Associate (CRA) Lunch and Learn training program, to be held on Wednesday, May 13th, 2026, at 12 pm ET on the topic: NCTN Clinical Trial Support Unit (CTSU) OPEN System and upcoming changes
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy.
Kingston, ON – Jan. 30, 2026 – Decades of cancer research—and thousands of patient tumour samples — now have a new home at Kingston Health Sciences Centre (KHSC) and this state-of-the-art space will change how researchers study cancer in the future.
October 28, 2025 New York, NY – The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) announced the enrollment of the first patient in the third substudy of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) (NCT04918186).
Berlin, 20 October 2025 - AGITG DYNAMIC-III clinical trial findings published in Nature Medicine and presented at the Presidential Symposium of the European Society for Medical Oncology Congress in Berlin, Germany. Globally significant results show circulating tumour DNA (ctDNA) is feasible to guide treatment choices for stage 3 colon cancer. The randomised Phase 2/3 clinical trial randomised 1,002 patients from Australia, Aotearoa New Zealand, and Canada.
Kingston (Ontario) – 1er juin 2025 – Dans le cadre d’un premier essai clinique international, des chercheurs travaillant avec le Groupe canadien des essais sur le cancer (GCEC) ont démontré qu’un programme d’exercice structuré améliore considérablement la survie des patients atteints du cancer du côlon en réduisant le risque de récidive de la maladie et d’apparition de nouveaux cancers primaires.
Kingston, Ontario— June 1, 2025 — In a world-first clinical trial, researchers working with the Canadian Cancer Trials Group (CCTG) have demonstrated that a structured exercise program significantly improves survival for colon cancer patients by reducing the risk of disease recurrence and new primary cancers.
Umbrella trial design will link multiple NCI-supported studies to allow patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to register to clinical trials throughout the course of their cancer treatment.
The Journal of Clinical Oncology has published 'Correlative Science in the Cooperative Group System—Re-Engineering for Success,' which proposes public-private partnerships to increase resources and process innovations to open access to tissue banks.
The AGITG TOPGEAR study led by the Australasian Gastro-Intestinal Trials Group (AGITG) and coordinated by the NHMRC Clinical Trials Centre (NHMRC CTC) at the University of Sydney, has announced the first randomised evidence of preoperative chemoradiotherapy for gastric cancer.
February 29, 2024—Kingston ON The Canadian led HE1 trial results, published in Lancet Oncology, confirm the quality-of-life benefits of palliative radiation therapy for symptom
Montréal, le 15 mai 2024 – La Société canadienne du cancer (SCC) s’associe à une équipe de 12 chercheurs et collaborateurs pour mener l’un des plus grands essais cliniques randomisés contrôlés du monde utilisant la transplantation de microbiote fécal (TMF ou FMT en anglais) pour améliorer l’efficacité des traitements du mélanome avancé. Cet essai de phase II est rendu possible grâce à deux investissements de 1 M$ de la SCC et de la Fondation de la famille Weston, et il sera supervisé par le Groupe canadien des essais sur le cancer.
Montreal, May 15, 2024 - The Canadian Cancer Society (CCS) is uniting with a team of 12 researchers and collaborators to lead one of the world’s largest randomized controlled clinical trials using fecal microbiota transplantation (FMT) to improve the effectiveness of the standard of care for advanced melanoma. This phase II trial is made possible by investments of $1 million each from CCS and the Weston Family Foundation and will be overseen by the Canadian Cancer Trials Group.
Les résultats de l’étude CX5/SHAPE publiée aujourd’hui dans le New England Journal of Medicine (NEJM) conclut qu’une hystérectomie simple est une option de traitement sécuritaire pour les femmes atteintes d’un cancer du col de l’utérus à un stade précoce et de faible risque. Cette étude internationale de Phase III a comparé l’hystérectomie radicale et évaluation ganglionnaire avec l’hystérectomie simple et évaluation ganglionnaire.
February 29, 2024—Kingston ON | Montreal QC — The results of the CX5/SHAPE clinical trial, published today in the New England Journal of Medicine (NEJM), conclude that a simple hysterectomy is a safe treatment option for women with low-risk early-stage cervical cancer. The Phase III international trial compared radical hysterectomy and pelvic node dissection with simple hysterectomy and pelvic node dissection.
Results from a phase III international study (IND.227) were published today in The Lancet and evaluated the use of the immunotherapy drug pembrolizumab combined with platinum-pemetrexed chemotherapy. Researchers conclude that as a first-line treatment for patients with unresectable advanced or metastatic pleural mesothelioma, pembrolizumab plus platinum-pemetrexed chemotherapy represents a new treatment option for patients.
KINGSTON, ONTARIO – June 30, 2023 – Dr. Joseph Pater has been recognized for a lifetime of work in cancer research with his appointment as an Officer of the Order of Canada. The honor acknowledges the impact of his dedication to clinical research which has improved the lives of Canadians with cancer.
KINGSTON, Ontario, June 3, 2023 – Late-breaking results for the IND.227 trial were presented today during an oral abstract at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase III international study evaluated the use of the immunotherapy drug pembrolizumab combined with platinum-pemetrexed chemotherapy as a first-line treatment for patients with unresectable advanced or metastatic pleural mesothelioma.
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone.
Kingston, Ontario – June 2, 2023 - A simple hysterectomy with pelvic node dissection is a safe treatment option for women with low-risk early-stage cervical cancer and may help improve quality of life, according to results from the CX5/SHAPE study, an international phase III clinical trial led by the Canadian Cancer Trials Group in collaboration with The Gynecological Cancer InterGroup (GCIG). The research findings were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
RAHWAY, N.J., and KINGSTON, ON, Mar. 10, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma.
KINGSTON, ON – January 20, 2023 – Late breaking results shared today at the ASCO Gastrointestinal Cancer Symposium for the Canadian Cancer Trials Group (CCTG) HE1 phase III study of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases.
KINGSTON, ONTARIO - August 19, 2022 - The Canadian Cancer Trials Group (CCTG) Operations and Statistics Centre will receive full funding of $19,457,683 through The Major Science Initiatives (MSI) Fund. Minister of Innovation, Science and Industry, François-Philippe Champagne announced the award at Queen’s University as part of the 19 successful research infrastructure projects receiving $628 million from the Canada Foundation for Innovation (CFI). The funding supports state-of-the-art facilities of national importance to drive innovative research in Canada.
FIRST PATIENTS DOSED IN PHASE 2 PLATFORM CLINICAL TRIAL TESTING NOVEL IMMUNOTHERAPY COMBINATIONS IN HIGHLY MALIGNANT OVARIAN CANCER
KINGSTON, ON – April 6, 2022 – The Canadian Cancer Society (CCS) has renewed its support of the Canadian Cancer Trials Group (CCTG) with a five-year 30-million-dollar commitment to the national research network. The grant renewal represents a continuation of CCS’s largest research investment, which began in 1980 when they helped create the Canadian academic research group.
TORONTO, Dec. 7, 2021 /CNW/ - A widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most common forms of the disease, according to new findings.
FOR IMMEDIATE RELEASE
Practice changing trial results show new radiation treatment improves pain relief for cancer patients.
Infrastructure funding to launch ExCELLirate Canada, a National Research Platform for Next Generation Cancer Cell Therapies
Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Br
ARLINGTON, Va. October 26, 2020 — A new study shows using fewer and higher doses of high-precision radiation therapy is a more effective approach for treating painful spinal tumors than conventional radiation therapy. More than twice as many patients treated with stereotactic body radiation therapy (SBRT) reported an enduring, complete reduction in pain, compared to those treated with conventional radiation.
NEW YORK--(BUSINESS WIRE)-- The Canadian Cancer Trials Group (CCTG) today announced the commencement of a new sub-study evaluating CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 (PLK4), in patients with metastatic castrate-resistant prostate cancer (mCRPC).
January 19, 2019 Kingston, Ontario - Today at the American Society of Clinical Oncology 2019 Gastrointestinal Cancers Symposium in San Francisco the ground breaking results of Canadian Cancer Trials Group (CCTG) CO.26 study were presented. This Canadian study is the first randomized clinical trial to demonstrate an overall survival benefit for immune checkpoint therapy in patients with colorectal cancer whose tumours were not mismatch repair deficient (dMMR).
December 20, Paris, France and Kingston, Ontario – The results of the Unicancer and the Canadian Cancer Trials Group (CCTG) PRODIGE 24 | CCTG PA.6 study have been published in the New England Journal of Medicine. The practice changing results indicate a significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy compared to the current standard treatment with gemcitabine
IND.234 is the first prostate precision medicine trial to use liquid biopsies for genomic testing
Vancouver and Kingston - November 27, 2018 – A new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world. The IND.234 clinical trial, conducted by the Canadian Cancer Trials Group (CCTG), uses liquid biopsy technology to screen for genomic markers in prostate cancer patients.
For immediate release
New international research collaboration explores blood-based biomarker testing to identify cancer patients that could potentially respond to immunotherapy
The study explores a potential non-invasive approach to identify tumor mutations
Kingston, Ontario – August 13, 2018 – The Canadian Institute of Health Research (CIHR) has announced a project grant award of $860,628 over six years for a research project lead by the Canadian Cancer Trials Group (CCTG). The HN.10 study will investigate the potential benefits of the de-escalation of treatment for patients with tonsil cancer.
For Immediate Release
Kingston, Ontario – June 4, 2018 – Clinical trial results presented today at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago show substantial increased survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
NEW YORK and KINGSTON, ON, Jan.
The Canadian Cancer Trials Group (CCTG) led CE.6 phase III trial was published today in the New England Journal of Medicine. This international study tested the addition of temozolomide chemotherapy to an abbreviated course of radiation therapy in older adults with Glioblastoma (brain cancer).
Tragically Hip recognized for supporting brain cancer research
Today, the Canadian Cancer Society (CCS) recognized Kingston hometown heroes the Tragically Hip for their support of brain cancer research. A commemorative plaque was presented to the band in honour of their support for cancer clinical trials at the Canadian Cancer Trials Group (CCTG).
CCTG, housed at Queen’s University in Kingston, is supported by a core grant from the Canadian Cancer Society.
KINGSTON, ON, April 23, 2019 - The Canadian Cancer Trials Group (CCTG) has been awarded more than 19 million USD over six years (approximately $25 million CAD) from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI). This award will allow the group to continue their work leading major cancer clinical trials in Canada through the US National Clinical Trials Network (NCTN) and to develop new large scale trials under CCTG leadership.
